Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | NCK1 | P16333 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256198 | 0.88 | NOS3 (0.50) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL4497002 | 0.84 | BACE1 (0.47) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL4499287 | 0.84 | NOS3 (0.47) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL4581784 | 0.84 | NOS3 (0.47) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL11008096 | 0.83 | NOS3 (0.50) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL28335499 | 0.83 | MEN1 (0.51) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL11069575 | 0.82 | NOS3 (0.48) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL1528907 | 0.81 | KMT2A (0.49) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL16835898 | 0.80 | NOS3 (0.47) | NOS3NOS2NOS1MEN1KMT2A | |
| SCHEMBL17795529 | 0.78 | CYP1A2 (0.40) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | NOS3 1649/4885NOS2 1792/4885NOS1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.